Biogen Inc. completed the spinoff of its global hemophilia unit.

The new company, Bioverativ, is an independent publicly traded global biotechnology company specializing in hemophilia and other rare blood disorders, Biogen said in a news release.

Bioverativ common stock will begin regular way trading Feb. 2 on the Nasdaq Global Select Market under the symbol BIVV.

Biogen was advised by Goldman Sachs & Co. and Guggenheim Securities LLC.